Education
About Us
Working with TipRanks
Follow Us
Protara Therapeutics (TARA)
NASDAQ:TARA
Total Valuation
Protara Therapeutics has a market cap or net worth of $138.11M. The enterprise value is -$26.25M.
Market Cap$138.11M
Enterprise Value-$26.25M
Share Statistics
Protara Therapeutics has 38,579,020 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding38,579,020
Owned by Insiders9.48%
Owned by Institutions54.89%
Financial Efficiency
Protara Therapeutics’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is -28.64%.
Return on Equity (ROE)-0.27
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)-28.64%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee0.00
Profits Per Employee-1.59M
Employee Count28
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Protara Therapeutics is -2.44. Protara Therapeutics’s PEG ratio is 0.06.
PE Ratio-2.44
PS Ratio0.00
PB Ratio0.65
Price to Fair Value0.65
Price to FCF-3.03
Price to Operating Cash Flow-3.04
PEG Ratio0.06
Income Statement
In the last 12 months, Protara Therapeutics had revenue of 0.00 and earned -44.60M in profits. Earnings per share was -2.17.
Revenue0.00
Gross Profit0.00
Operating Income-49.15M
Pretax Income-44.60M
Net Income-44.60M
EBITDA-49.15M
Earnings Per Share (EPS)-2.17
Cash Flow
In the last 12 months, operating cash flow was -35.81M and capital expenditures -63.00K, giving a free cash flow of -35.87M billion.
Operating Cash Flow-35.81M
Free Cash Flow-35.87M
Free Cash Flow per Share-0.93
Dividends & Yields
Protara Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.50
52-Week Price Change23.02%
50-Day Moving Average4.00
200-Day Moving Average3.36
Relative Strength Index (RSI)42.65
Average Volume (3m)446.74K
Important Dates
Protara Therapeutics upcoming earnings date is Aug 11, 2025, TBA Not Confirmed.
Last Earnings DateMay 1, 2025
Next Earnings DateAug 11, 2025
Ex-Dividend Date―
Financial Position
Protara Therapeutics as a current ratio of 15.71, with Debt / Equity ratio of 2.68%
Current Ratio15.71
Quick Ratio15.71
Debt to Market Cap0.04
Net Debt to EBITDA3.22
Interest Coverage Ratio-11.78
Taxes
In the past 12 months, Protara Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Protara Therapeutics EV to EBITDA ratio is 1.01, with an EV/FCF ratio of 1.38.
EV to Sales0.00
EV to EBITDA1.01
EV to Free Cash Flow1.38
EV to Operating Cash Flow1.38
Balance Sheet
Protara Therapeutics has $170.29M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$165.81M billion.
Cash & Marketable Securities$170.29M
Total Debt$0.00
Net Cash-$165.81M
Net Cash Per Share-$4.30
Tangible Book Value Per Share$7.96
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Protara Therapeutics is $21.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$21.75
Price Target Upside507.54% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast32.58%